News | August 31, 2011

Medtronic Starts New U.S. Study of Endurant AAA Stent Graft

August 31, 2011 — Medtronic Inc. announced the start of its United States post-approval study of the Endurant AAA stent graft system, a medical device used to treat abdominal aortic aneurysms (AAA).

The first patient in the Post-Approval Study Evaluating the Long-Term Safety and Effectiveness of the Endurant Stent Graft System (ENGAGE PAS) was enrolled earlier this month at Parkwest Medical Center in Knoxville, Tenn. The site’s principal investigator (PI), vascular surgeon Christopher Pollock, M.D., enrolled the patient.

The national PI is Marc Schermerhorn, M.D., chief of vascular and endovascular surgery at Beth Israel Deaconess Medical Center and associate professor of surgery at Harvard Medical School in Boston.

“The ENGAGE clinical program exemplifies Medtronic’s commitment to characterize the real-world, long-term performance of the Endurant AAA Stent Graft,” Schermerhorn said. “The resulting data will help clinicians worldwide improve their minimally invasive treatment of patients with abdominal aortic aneurysms.”

ENGAGE PAS is a prospective, multi-center, single-arm study designed to demonstrate the long-term safety and effectiveness of the Endurant AAA stent graft in a post-market environment. The study will involve approximately 325 subjects and up to 25 United States sites. The primary endpoint of ENGAGE PAS is freedom from aneurysm-related mortality at five years after implantation of the stent graft.

The study augments Medtronic’s international ENGAGE Registry, the largest real-world collection of clinical data on a single stent graft ever compiled. Completed in April, the registry enrolled 1,266 patients over two years at 79 sites across 29 countries.

In total, more than 1,800 patients treated with the system will be followed out to five years as part of Medtronic’s global clinical program for the device. The program includes company-sponsored pre- and post-market studies conducted worldwide since November 2007, when the first-in-human implant was performed in the Netherlands.

The U.S. Food and Drug Administration (FDA) approved the Endurant AAA stent graft system in December 2010. Since then, the device has been used to treat more than 6,000 patients in the United States. It is the market-leading stent graft worldwide.

The Endurant is a flexible wire frame (stent) sewn onto a specially woven fabric tube (graft) physicians use to create a new path for blood flow in the patient’s aorta; this reduces pressure on the aneurysm and the risk of rupture. Delivered through catheters inserted into blood vessels in the groin, the device conforms to a broad range of aortic anatomies; this enables physicians to offer endovascular aortic repair (EVAR) to more AAA patients than ever before.

In the United States, the system is indicated for the endovascular treatment of infrarenal abdominal aortic and aorto-iliac aneurysms in patients with specific anatomical characteristics; these include adequate femoral or iliac artery access, proximal neck length at least 10 mm, infrarenal neck angulation no greater than 60 degrees, and aortic neck diameter of 19 to 32 mm.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init